| |
DFSª
|
BCSSb
|
OSb
|
|---|
| |
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
HR
|
95% CI
|
P
|
|---|
|
BM3-pos vs. BM3-neg
|
2.2
|
1.3-3.9
|
0.005
|
2.6
|
1.4-4.7
|
0.002
|
2.6
|
1.4-4.4
|
0.002
|
|
cN status (vs. N0)
| | |
0.053
| | |
0.032
| | |
0.047
|
|
cN1
|
2.0
|
1.0-3.8
|
0.040
|
2.3
|
1.1-4.8
|
0.019
|
2.2
|
1.1-4.3
|
0.024
|
|
cN 2-4
|
2.4
|
1.0-5.6
|
0.034
|
2.7
|
1.1-6.6
|
0.027
|
2.4
|
1.0-5.6
|
0.049
|
|
PgR-pos vs. PgR-neg
|
1.3
|
0.7-2.7
|
0.429
|
1.8
|
0.9-3.8
|
0.118
|
1.5
|
0.8-3.1
|
0.239
|
|
ER-pos vs. ER-neg
|
0.9
|
0.4-2.0
|
0.796
|
1.0
|
0.5-2.4
|
0.919
|
0.9
|
0.4-2.1
|
0.897
|
|
PB1-pos vs. PB1-neg
| | | |
2.2
|
0.3-19.1
|
0.482
|
2.2
|
0.3-17.8
|
0.496
|
|
Grade 3 vs.grade 1-2
|
1.1
|
0.8-1.5
|
0.648
|
1.1
|
0.6-2.3
|
0.703
|
1.3
|
0.7-2.5
|
0.482
|
- ªDisease-free survival (DFS) analyzed only in stage M0 patients.
- bBreast cancer-free survival (BCSS) and overall survival (OS) analyzed in all patients.
- Pos: positive; neg: negative; BM3: bone marrow aspiration pretreatment; cN: clinical node status; PgR: progesterone receptor; ER: estrogen receptor; PB1: peripheral blood sampling pretreatment.
